ahlam1399
09-30-2016, 04:51 PM
Regeneron?s Eylea combination therapy fails mid-stage study
Sept 30 (Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug,Eylea, was inferior to Eylea alone in a mid-stage trialinvolving patients with wet age-related macular degeneration(AMD), a leading cause of blindness.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=YoDFD_Q9WOQ:wnCg0m6Mc2g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=YoDFD_Q9WOQ:wnCg0m6Mc2g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/YoDFD_Q9WOQ
Sept 30 (Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug,Eylea, was inferior to Eylea alone in a mid-stage trialinvolving patients with wet age-related macular degeneration(AMD), a leading cause of blindness.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=YoDFD_Q9WOQ:wnCg0m6Mc2g:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=YoDFD_Q9WOQ:wnCg0m6Mc2g:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=YoDFD_Q9WOQ:wnCg0m6Mc2g:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/YoDFD_Q9WOQ